218 related articles for article (PubMed ID: 26365295)
1. Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer Cells.
Li J; Kuang Y; Shi J; Zhou J; Medina JE; Zhou R; Yuan D; Yang C; Wang H; Yang Z; Liu J; Dinulescu DM; Xu B
Angew Chem Int Ed Engl; 2015 Nov; 54(45):13307-11. PubMed ID: 26365295
[TBL] [Abstract][Full Text] [Related]
2. Kinetic Analysis of Nanostructures Formed by Enzyme-Instructed Intracellular Assemblies against Cancer Cells.
Li J; Bullara D; Du X; He H; Sofou S; Kevrekidis IG; Epstein IR; Xu B
ACS Nano; 2018 Apr; 12(4):3804-3815. PubMed ID: 29537820
[TBL] [Abstract][Full Text] [Related]
3. Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells.
Shin SY; Jung H; Ahn S; Hwang D; Yoon H; Hyun J; Yong Y; Cho HJ; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2014 Mar; 22(6):1809-20. PubMed ID: 24565968
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
5. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
Yu R; Jin H; Jin C; Huang X; Lin J; Teng Y
Cell Biochem Funct; 2018 Mar; 36(2):80-87. PubMed ID: 29372560
[TBL] [Abstract][Full Text] [Related]
8. Selectively Inducing Cancer Cell Death by Intracellular Enzyme-Instructed Self-Assembly (EISA) of Dipeptide Derivatives.
Li J; Shi J; Medina JE; Zhou J; Du X; Wang H; Yang C; Liu J; Yang Z; Dinulescu DM; Xu B
Adv Healthc Mater; 2017 Aug; 6(15):. PubMed ID: 28233466
[TBL] [Abstract][Full Text] [Related]
9. Triple-combination therapy assisted with ultrasound-active gold nanoparticles and ultrasound therapy against 3D cisplatin-resistant ovarian cancer model.
Kip B; Tunc CU; Aydin O
Ultrason Sonochem; 2022 Jan; 82():105903. PubMed ID: 34974392
[TBL] [Abstract][Full Text] [Related]
10. Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells.
He C; Lu K; Liu D; Lin W
J Am Chem Soc; 2014 Apr; 136(14):5181-4. PubMed ID: 24669930
[TBL] [Abstract][Full Text] [Related]
11. Short divalent ethacrynic amides as pro-inhibitors of glutathione
Xu B; Tong T; Wang X; Liu F; Zhang X; Hu X; Li X; Yang X; Liao F
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):728-742. PubMed ID: 35176963
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
Gong TT; Liu XD; Zhan ZP; Wu QJ
Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
[TBL] [Abstract][Full Text] [Related]
13. Enzyme-Regulated Supramolecular Assemblies of Cholesterol Conjugates against Drug-Resistant Ovarian Cancer Cells.
Wang H; Feng Z; Wu D; Fritzsching KJ; Rigney M; Zhou J; Jiang Y; Schmidt-Rohr K; Xu B
J Am Chem Soc; 2016 Aug; 138(34):10758-61. PubMed ID: 27529637
[TBL] [Abstract][Full Text] [Related]
14. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F
Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260
[TBL] [Abstract][Full Text] [Related]
15. Mitochondria-targeting zeolitic imidazole frameworks to overcome platinum-resistant ovarian cancer.
Xing Y; Jiang Z; Akakuru OU; He Y; Li A; Li J; Wu A
Colloids Surf B Biointerfaces; 2020 May; 189():110837. PubMed ID: 32058250
[TBL] [Abstract][Full Text] [Related]
16. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
18. Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer.
Choi SH; Jung D; Kim KY; An HJ; Park KS
Biochem Biophys Res Commun; 2021 Jul; 563():40-46. PubMed ID: 34058473
[TBL] [Abstract][Full Text] [Related]
19. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
20. Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers.
Bhosale SS; Mandal A; Hou C; McCorkle JR; Schweer D; Hill KS; Subramanian V; Kolesar JM; Tsodikov OV; Rohr J
ChemMedChem; 2023 Feb; 18(3):e202200368. PubMed ID: 36342449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
